Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-08-04
2000-02-08
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514252, 544 60, 544364, A61K 31495, C07D29504
Patent
active
060228695
DESCRIPTION:
BRIEF SUMMARY
The invention relates to a group of aminoheterocyclic derivatives, and pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the preparation of said aminoheterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.
The antithrombotic and anticoagulant effect produced by the compounds of the invention is believed to be attributable to their strong inhibitory effect against the activated coagulation protease known as Factor Xa. Factor Xa is one of a cascade of proteases involved in the complex process of blood coagulation. The protease known as thrombin is the final protease in the cascade and Factor Xa is the preceding protease which cleaves prothrombin to generate thrombin.
Certain compounds are known to possess Factor Xa inhibitory properties and the field has been reviewed by R. B. Wallis, Current Opinion in Therapeutic Patents, 1993, 1173-1179. Thus it is known that two proteins, one known as antistasin and the other known as tick anticoagulant protein (TAP), are specific Factor Xa inhibitors which possess antithrombotic properties in various animal models of thrombotic disease.
It is also known that certain non-peptidic compounds possess Factor Xa inhibitory properties. Of the low molecular weight inhibitors mentioned in the review by R. B. Wallis, all possessed a strongly basic group such as an amidinophenyl or amidinonaphthyl group.
It is the object of the present invention to provide a new class of agent which lacks the amidino group previously believed to be an essential feature for a Factor Xa inhibitor.
We have now found that certain amino-substituted heterocyclic derivatives possess Factor Xa inhibitory activity and in particular also possess the advantage of being selective Factor Xa inhibitors, that is the enzyme Factor Xa is inhibited strongly at concentrations of test compound which do not inhibit or which inhibit to a lesser extent the enzyme thrombin which is also a member of the blood coagulation enzymatic cascade.
The compounds of the present invention possess activity in the treatment or prevention of a variety of medical disorders where anticoagulant therapy is indicated, for example in the treatment or prevention of thrombotic events associated with coronary artery and cerebro-vascular disease. Further examples of such medical disorders include various cardiovascular and cerebrovascular conditions such as myocardial infarction, the formation of atherosclerotic plaques, venous or arterial thrombosis, coagulation syndromes, disseminated intravascular coagulation, vascular injury including reocclusion and restenosis following angioplasty and coronary artery bypass surgery, thrombus formation after the application of blood vessel operative techniques or after general surgery such as hip replacement surgery, the introduction of artificial heart valves or on the recirculation of blood, cerebral infarction, cerebral thrombosis, stroke, cerebral embolism, pulmonary embolism, ischaemia and angina (including unstable angina).
The compounds of the invention are also useful as inhibitors of blood coagulation in an ex-vivo situation such as, for example, the storage of whole blood or other biological samples suspected to contain Factor Xa and in which coagulation is detrimental.
According to one aspect of the invention there is provided an aminoheterocyclic derivative of formula I, ##STR1## wherein G.sup.1 and G.sup.2 independently represent CH or N; m is 0, 1 or 2; R.sup.6, hydroxy, nitro, (1-4C)alkyl or (1-4C)alkoxy; (1-3C)alkylene-carbonyl; or R.sup.2 and R.sup.3 together form a (1-4C)alkylene or methylenecarbonyl group,
wherein 1 or 2 methylene groups within L.sup.1 or the ring formed when R.sup.2 and R.sup.3 are linked optionally bears 1 or 2 substituents selected from carboxy, CONR.sup.5 R.s
REFERENCES:
patent: 4537896 (1985-08-01), Claeson et al.
R.B. Wallis, "Inhibitors of Coagulation Factor Xa: From Macromolecular Beginnings to Small Molecules", Current Opinion in Therapeutic Patents, 1173-1179 (1993).
J.R. Smith et al., "Fibrin, Red Cell and Platelet Interactions in an Experimental Model of Thrombosis", Br. J. Pharmac., 77:029-038 (1982).
G. Vogel et al., "Comparison of Two Experimental Thrombosis Models in Rats Effects of Four Glycosaminoglycans", Thromb. Res., 54:399-410 (1989).
C. Kettner et al., "The Selective Inhibition of Thrombin by Peptides of Boroarginine", J. Biol. Chem., 265 (30) :18289-18297 (1990).
E. Jucker, "Uber C-substituierte Piperazinderivate", Helv. Chim. Acta, 45:2383-2042 (1962).
McKane Joseph K.
Zeneca Limited
LandOfFree
Aminoheterocyclic compounds with antithrombotic/anticoagulant ef does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoheterocyclic compounds with antithrombotic/anticoagulant ef, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoheterocyclic compounds with antithrombotic/anticoagulant ef will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1681615